UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~January~~February 2711, 2015

SIGNPATH PHARMA INC.

(Exact name of registrant as specified in its charter)

Delaware	333-158474	20-5079533
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3477 Corporate Parkway, Suite 100, Center Valley, PA 18034

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (215) 538-9996

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 4.01 CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT

(ab) ~~Dismissal~~Engagement of New Independent Registered Accounting Firm

On ~~January~~February 2711, 2015, ~~the Board of Directors (the “Board”) and the Audit Committee of the Board (the “Audit Committee”) of~~ SignPath Phama Inc., a Delaware corporation (the “Company”), ~~approved~~engaged ~~the~~Friedman ~~termination~~LLP ~~of M&K CPAS, PLLC~~ (“~~M&K~~Friedman”) as the Company’s new Independent Certified Public Accountants. Friedman ~~for~~will perform the audit of the Company’s consolidated financial statements for the fiscal year ended December 31, 2014. The ~~Chairman~~Company’s ofaudit ~~the~~committee ~~Audit~~participated ~~Committee~~in ~~sent~~and ~~M&K~~approved athe ~~termination~~decision ~~letter~~to onappoint ~~January 29, 2015~~Friedman.

During the ~~Company’s~~ two most recent fiscal years and ~~in the subsequent interim period~~ through the date of ~~this~~its ~~Form 8-K~~appointment, ~~(i)~~neither ~~there~~the ~~were~~Company, nonor ~~disagreements~~anyone ~~between~~on ~~the~~its ~~Company~~behalf, ~~and~~consulted ~~M&K~~Friedman onregarding ~~any~~(i) ~~matter~~either the application of accounting principles orto ~~practices~~a specified transaction, ~~financial~~either ~~statement~~completed ~~disclosure~~or proposed, or ~~auditing~~the ~~scope~~type orof ~~procedure~~audit ~~which,~~opinion ifthat ~~not~~might ~~resolved~~be torendered on the ~~satisfaction~~Company’s offinancial ~~the~~statements, ~~former~~and ~~accountant,~~neither ~~would~~a ~~have~~written ~~caused~~report itnor tooral ~~make~~advice ~~reference~~was provided to the ~~subject~~Company ~~matter~~by ofFriedman that it concluded was an important factor considered by the ~~disagreement~~Company in ~~connection~~reaching ~~with~~a ~~its~~decision ~~reports~~as onto the ~~Company’s~~accounting, auditing or financial ~~statements~~reporting issue; ~~and~~or (ii) ~~there~~any ~~were~~matter nothat ~~reportable~~was ~~events~~either the subject of a “disagreement” (as ~~described~~defined in ~~paragraph~~Item 304(a)(1)(viv) of Regulation S-K and the related instructions) or a “reportable event” as defined in Item 304(a)(1)(v) of Regulation S-K.

The reports of M&K on the Company’s consolidated financial statements for the fiscal years ended December 31, 2013 and 2012 did not contain an adverse opinion or disclaimer of opinion, or qualified opinion, audit scope, or accounting principles, except for an explanatory paragraph in the audit reports for such fiscal years indicating substantial doubt about the Company’s ability to continue as a going concern.

The Company provided M&K with a copy of the foregoing disclosures and requested it to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether M&K agrees with the statements made by the Company in this Report. A copy of the letter has been filed as Exhibit 16.1 to this Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

Exhibit Number		Description
16.1		Letter from M&K CPAS, PLLC, dated February 2, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SIGNPATH PHARMA INC.
Dated: February 2, 2015	By:	/s/ Lawrence Helson
Dated: February 13, 2015	By:	/s/ Lawrence Helson
		Name: Lawrence Helson, M.D.
		Title: Chief Executive Officer

Filing Compare · SignPath Pharma, Inc.